New Cancer Nanomedicine Reduces Pancreatic Tumor Growth
Australian cancer researchers have developed a highly promising nanomedicine technology to deliver gene-silencing drugs to treat pancreatic cancer – the most chemo-resistant and deadly cancer in Australia.
When tested in mice, the new nanomedicine resulted in a 50 per cent reduction in the growth of tumours and reduced the spread of pancreatic cancer.
The University of New South Wales-led research, published in the Biomacromolecules journal, provides new hope for pancreatic cancer patients, most of whom succumb to the disease within three to six months of diagnosis. Read more . . .